Stem Cells for Back Pain, Spine and Cervical Conditions:

New Cellular Treatment Possibilities for Back Pain Conditions.

Stem Cells for Back Pain, Spine and Cervical Conditions:
New Cellular Treatment Possibilities for Back Pain Conditions.

Back pain and spinal conditions are usually treated by invasive methods, such as spinal and back operations (surgeries), as well as with medications and injections that target the painful symptoms.

Both operations and pain relief medications seldom satisfy the patient, as shown by statistics conducted in clinical institutions. This does not come as a surprise, because none of these options offer any real solution to the root of the problem. While these common treatments can offer improvements (and are sometimes even necessary), the choice of the correct treatment option depends on the origin and the severity of the pain. Is a surgical procedure necessary? And if yes, what can patients expect as an outcome?

In general, before the decision for getting an operation for back pain relief is considered, all other methods should be carefully evaluated. An exception to this rule is when there is an immediate need for a surgical intervention, for instance in cases with entire loss of control in the leg(s). However, back pain operations are not at all a 100% guarantee that the patient will fully recover and live a pain-free life – quite often the opposite result happens.

The ANOVA Stem Cell Treatment for Back Pain:
A promising therapy option that works on a cellular level.

In animal models of disc degeneration, MSCs have shown to restore normal disc structure. Since disc degeneration seems to depend on alterations of nucleus pulposus (NP) cells, Strassburg and colleagues have investigated the interactions between MSCs and degenerated NP cells, in greater detail.

Similar to other degenerative diseases where stem cell therapies have been proven to be successful (i.e. neurodegenerative diseases), they found that the two cell types primarily communicate via an extensive direct transfer of membrane components and extracellular vesicles, which is known as the Stem Cell Secretome.

Stem Cell Treatment of Degenerated Discs and Back PainFigure: Schematic illustration of discogenic degenerative diseases of the disc – one of the most frequent sources of back pain.

Stem cells can trigger regenerative effects by improving the problems at the root, where the catabolic microenvironment causes bad disc quality due to minimal cell proliferation. Stem cells can help with their intrinsic inter-cellular communication factors, the so called paracrine factors, also known as the Stem Cell Secretome. The ANOVA Stem Cell Secretome therapy is designed to harness and concentrate these factors.

ANOVA Institute for Regenerative Medicine has moved long past a one-fits-all stem cell therapy. Different cell therapies have been proven to be efficient for different back pain and spinal conditions, syndromes and degenerations. All of these, namingly Bone Marrow Concentrate (BMC), Mesenchymal Stem Cells (MSC), Platelet Rich Plasma (PRP) and tissue transplants grown from stem cells have shown to induce regenerative effects for different orthopedic pathologies.

ANOVA offers these treatments in a personalized treatment plan, based on your current health status. As with any type of treatment, experimental therapy such as stem cell-based therapy cannot promise any success. Before the attending physician can suggest an experimental therapy, they will individually assess whether the benefits of the therapy are given for the patient and make sure they outweigh the potential risks. With this approach, ANOVA establishes a safe method to offer cellular regenerative treatment for back pain and spinal conditions in cases where it is beneficial. Unmatched quality worldwide and developed by a team of German scientists and medical professionals in a dedicated private German institute.

If you are interested to apply for a stem cell-based treatment for back pain, of wish to know more information, please feel free to contacts us.

This treatment may significantly be enhanced by a therapeutic combination with Infusion Therapy. If you are interested to learn more about the combination therapy, click “I am interested in Infusion Therapy” on our Contact Page.
References and Literature - Stem Cell-based Therapies for Back Pain and Spinal Conditions (Click for more)

[1] Zeckser, J., Wolff, M., Tucker, J., & Goodwin, J. (2016). Multipotent Mesenchymal Stem Cell Treatment for Discogenic Low Back Pain and Disc Degeneration, 2016, 4–6.
[2] Baglio, Serena Rubina, Dirk Michiel Pegtel, and Nicola Baldini. "Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy." Frontiers in physiology 3 (2012): 359.
[3] Richardson, Stephen M., et al. "Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration." Methods 99 (2016): 69-80.
[4] Strassburg, Sandra, et al. "Bi-directional exchange of membrane components occurs during co-culture of mesenchymal stem cells and nucleus pulposus cells." PLoS One 7.3 (2012): e33739.
[4] K. A. Pettine, M. B. Murphy, R. K. Suzuki, and T. T. Sand, “Percutaneous lumbar intradiscal injection of autologous bone marrowconcentrated cells significantly reduces discogenic pain through 12 months,” Stem Cells, vol. 33, no. 1, pp. 146–156, 2015.
[5] Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of the Phase 3 Program at JP Morgan Healthcare Conference, January 2015, [7] N. Bogduk, C. Aprill, and R. Derby, “Lumbar discogenic pain: state-of-the-art review,” Pain Medicine, vol. 14, no. 6, pp. 813– 836, 2013.
[8] M. J. DePalma, J. M. Ketchum, and T. R. Saullo, “Etiology of chronic low back pain in patients having undergone lumbar fusion,” Pain Medicine, vol. 12, no. 5, pp. 732–739, 2011.
[9] J. C. Iatridis, S. B. Nicoll, A. J. Michalek, B. A. Walter, and M. S. Gupta, “Role of biomechanics in intervertebral disc degeneration and regenerative therapies: what needs repairing in the disc and what are promising biomaterials for its repair?” Spine Journal, vol. 13, no. 3, pp. 243–262, 2013.
[10] N. Bogduk, Practice Guidelines for Spinal Diagnostic and Treatment Procedures, International Spine Intervention Society, San Diego, Calif, USA, 2nd edition, 2013.
[11] K. M.Malik, S. P.Cohen,D. R.Walega, and H. T. Benzon, “Diagnostic criteria and treatment of discogenic pain: a systematic review of recent clinical literature,” The Spine Journal, vol. 13, no. 11, pp. 1675–1689, 2013.
[12] U. G. Longo, N. Papapietro, S. Petrillo, E. Franceschetti, N. Maffulli, and V.Denaro, “Mesenchymal stem cell for prevention and management of intervertebral disc degeneration,” Stem Cells International, vol. 2012, Article ID 921053, 7 pages, 2012.
[13] H. T. J. Gilbert, J. A. Hoyland, and S. M. Richardson, “Stem cell regeneration of degenerated intervertebral discs: current status (Update),” Current Pain and Headache Reports, vol. 17, article 377, 2013.
[14] H. J. Braun, N. Wilcox-Fogel, H. J. Kim, M. A. Pouliot, A. H. S. Harris, and J. L. Dragoo, “The effect of local anesthetic and corticosteroid combinations on chondrocyte viability,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 20, no. 9, pp. 1689–1695, 2012.
[15] J. L. Dragoo, C. M. Danial, H. J. Braun, M. A. Pouliot, and H. J. Kim, “The chondrotoxicity of single-dose corticosteroids,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 20, no. 9, pp. 1809–1814, 2012.
[16] B. Peng, X. Pang, Y.Wu, C. Zhao, and X. Song, “A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic lowback pain,” Pain, vol. 149, no. 1, pp. 124–129, 2010.
[17] S.-H. Kim, S.-H. Ahn, Y.-W. Cho, and D.-G. Lee, “Effect of intradiscal methylene blue injection for the chronic discogenic low back pain: one year prospective follow-up study,” Annals of Rehabilitation Medicine, vol. 36, no. 5, pp. 657–664, 2012.
[18] W. Yin, K. Pauza, W. J. Olan, J. F. Doerzbacher, and K. J. Thorne, “Intradiscal injection of fibrin sealant for the treatment of symptomatic lumbar internal disc disruption: results of a prospective multicenter pilot study with 24-month follow-up,” Pain Medicine, vol. 15, no. 1, pp. 16–31, 2014.
[19] S.-Z. Wang, Y.-F. Rui, Q. Tan, and C. Wang, “Enhancing intervertebral disc repair and regeneration through biology: plateletrich plasma as an alternative strategy,” Arthritis Research & Therapy, vol. 15, no. 5, article 220, 2013.
[20] G. B. Gullung, W. Woodall, M. Tucci, J. James, D. Black, and R. McGuire, “Platelet-rich plasma effects on degenerative disc disease: analysis of histology and imaging in an animal model,” Evidence-Based Spine-Care Journal, vol. 2, no. 4, pp. 13–18, 2011.
[21] Y.A.Tuakli-Wosornu, A. Terry, K. Boachie-Adjei et al., “Lumbar intradiskal platelet-rich plasma (PRP) injections: a prospective, double-blind, randomized controlled study,” PM&R, 2015.
[22] L. Manchikanti, F. J. E. Falco, R. M. Benyamin et al., “An update of the systematic assessment of mechanical lumbar disc decompression with nucleoplasty,” Pain Physician, vol. 16, no. 2, pp. SE25–SE54, 2013.
[23] V. Singh, L. Manchikanti, A. K. Calodney et al., “Percutaneous lumbar laser disc decompression: an update of current evidence,” Pain Physician, vol. 16, no. 2, pp. 229–260, 2013.
[24] D. H. Jo and H. J. Yang, “The survey of the patient received the epiduroscopic laser neural decompression,” The Korean Journal of Pain, vol. 26, no. 1, pp. 27–31, 2013.
[25] W. C. H. Jacobs, S. M. Rubinstein, P. C. Willems et al., “The evidence on surgical interventions for low back disorders, an overviewof systematic reviews,” European Spine Journal, vol. 22, no. 9, pp. 1936–1949, 2013.
[26] W. Shohei, Y. Kuroda, F. Ogura, T. Shigemoto, and M. Dezawa, “Regenerative effects of mesenchymal stem cells: contribution of muse cells, a novel pluripotent stem cell type that resides in mesenchymal cells,” Cells, vol. 1, no. 4, pp. 1045–1060, 2012.
[27] P. Ghosh, R.Moore, B. Vernon-Roberts et al., “Immunoselected STRO-3+ mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs: laboratory investigation,” Journal of Neurosurgery: Spine, vol. 16, no. 5, pp. 479–488, 2012.
[28] C. J. Centeno, “Clinical challenges and opportunities of mesenchymal stem cells in musculoskeletal medicine,” PM&R, vol. 6, no. 1, pp. 70–77, 2014.
[29] A. Cond´e-Green, R. L. Rodriguez, S. Slezak, D. P. Singh, N. H. Goldberg, and J. Mclenithan, “Comparison between stromal vascular cells’ isolation with enzymatic digestion and mechanical processing of aspirated adipose tissue,” Plastic and Reconstructive Surgery, vol. 134, no. 4, p. 54, 2014.
[30] L.-L. Lu, Y.-J. Liu, S.-G. Yang et al., “Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials,” Haematologica, vol. 91, no. 8, pp. 1017–1026, 2006.
[31] H. Brisby, N. Papadimitriou, C. Brantsing, P. Bergh, A. Lindahl, and H. Barreto Henriksson, “The presence of local mesenchymal progenitor cells in human degenerated intervertebral discs and possibilities to influence these in vitro: a descriptive study in humans,” Stem Cells and Development, vol. 22, no. 5, pp. 804– 814, 2013.
[32] M. Tanaka, D. Sakai, A. Hiyama et al., “Effect of cryopreservation on canine and human activated nucleus pulposus cells: a feasibility study for cell therapy of the intervertebral disc,” BioResearch Open Access, vol. 2, no. 4, pp. 273–282, 2013.
[33] D. Coric, K. Pettine, A. Sumich, and M. O. Boltes, “Prospective study of disc repair with allogeneic chondrocytes,” Journal of Neurosurgery: Spine, vol. 18, no. 1, pp. 85–95, 2013.
[34] H. J.Meisel, V. Siodla, T. Ganey, Y.Minkus, W. C. Hutton, and O. J. Alasevic, “Clinical experience in cell-based therapeutics: disc chondrocyte transplantation: a treatment for degenerated or damaged intervertebral disc,” Biomolecular Engineering, vol. 24, no. 1, pp. 5–21, 2007.
[35] T. Miyamoto, T. Muneta, T. Tabuchi et al., “Intradiscal transplantation of synovial mesenchymal stem cells prevents intervertebral disc degeneration through suppression of matrix metalloproteinase-related genes in nucleus pulposus cells in rabbits,”Arthritis Research&Therapy, vol. 12,no. 6, articleR206, 2010.
[36] S. Strassburg, S. M. Richardson, A. J. Freemont, and J. A. Hoyland, “Co-culture induces mesenchymal stem cell differentiation and modulation of the degenerate human nucleus pulposus cell phenotype,” Regenerative Medicine, vol. 5, no. 5, pp. 701–711, 2010.
[37] Z. Sun, Z.-H. Liu, X.-H. Zhao et al., “Impact of direct cell cocultures on human adipose-derived stromal cells and nucleus pulposus cells,” Journal of Orthopaedic Research, vol. 31, no. 11, pp. 1804–1813, 2013.
[38] X. Li, J. P. Lee, G. Balian, and D. G. Anderson, “Modulation of chondrocytic properties of fat-derivedmesenchymal cells in cocultures with nucleus pulposus,”Connective Tissue Research, vol. 46, no. 2, pp. 75–82, 2005.
[39] C. LeVisage, S.W.Kim,K.Tateno, A.N. Sieber, J.P.Kostuik, and K. W. Leong, “Interaction of human mesenchymal stem cells with disc cells: changes in extracellular matrix biosynthesis,” Spine, vol. 31, no. 18, pp. 2036–2042, 2006.
[40] A.W. H. Gebraad, S. Miettinen, D.W. Grijpma, and S. P.Haimi, “Human adipose stem cells in chondrogenic differentiation medium without growth factors differentiate towards annulus fibrosus phenotype in vitro,” Macromolecular Symposia, vol. 334, no. 1, pp. 49–56, 2013.
[41] K.Wuertz, K. Godburn, C. Neidlinger-Wilke, J. Urban, and J. C. Iatridis, “Behavior of mesenchymal stem cells in the chemical microenvironment of the intervertebral disc,” Spine, vol. 33, no. 17, pp. 1843–1849, 2008.
[42] D. Sakai, J. Mochida, T. Iwashina et al., “Regenerative effects of transplanting mesenchymal stem cells embedded in atelocollagen to the degenerated intervertebral disc,” Biomaterials, vol. 27, no. 3, pp. 335–345, 2006.
[43] V. Y. L. Leung, D.M. K. Aladin, F. Lv et al., “Mesenchymal stem cells reduce intervertebral disc fibrosis and facilitate repair,” Stem Cells, vol. 32, no. 8, pp. 2164–2177, 2014.
[44] L. Orozco, R. Soler, C. Morera, M. Alberca, A. S´anchez, and J. Garc´ıa-Sancho, “Intervertebral disc repair by autologous mesenchymal bonemarrowcells: a pilot study,” Transplantation, vol. 92, no. 7, pp. 822–828, 2011.
[45] Mesoblast Limited, “Positive Spinal Disc Repair Trial Results Using Mesoblast Adult Stem Cells,” 2014, http://www.globenewswire. com/.
[46] A. Colombini, C. Ceriani, G. Banfi, M. Brayda-Bruno, and M. Moretti, “Fibrin in intervertebral disc tissue engineering,” Tissue Engineering Part B: Reviews, vol. 20, no. 6, pp. 713–721, 2014.
[47] B. R.Whatley and X.Wen, “Intervertebral disc (IVD): structure, degeneration, repair and regeneration,” Materials Science & Engineering C, vol. 32, no. 2, pp. 61–77, 2012.
[48] Y. Wang, Z.-B. Han, Y.-P. Song, and Z. C. Han, “Safety of mesenchymal stem cells for clinical application,” Stem Cells International, vol. 2012,Article ID 652034, 4 pages, 2012.
[49] G.Vadal'a, G. Sowa,M.Hubert, L. G.Gilbertson,V.Denaro, and J. D. Kang, “Mesenchymal stem cells injection in degenerated intervertebral disc: cell leakage may induce osteophyte formation,” Journal of Tissue Engineering and Regenerative Medicine, vol. 6, no. 5, pp. 348–355, 2012.
[50] W.-H. Chen, H.-Y. Liu, W.-C. Lo et al., “Intervertebral disc regeneration in an ex vivo culture system using mesenchymal stem cells and platelet-rich plasma,” Biomaterials, vol. 30, no. 29, pp. 5523–5533, 2009.
[51] Y. Zhu, M. Yuan, H. Y. Meng et al., “Basic science and clinical application of platelet-rich plasma forcartilage defects and osteoarthritis: a review,” Osteoarthritis and Cartilage, vol. 21, no. 11, pp. 1627–1637, 2013.
[52] C. S. Lee,O. A. Burnsed,V. Raghuram, J.Kalisvaart, B.D. Boyan, and Z. Schwartz, “Adipose stem cells can secrete angiogenic factors that inhibit hyaline cartilage regeneration,” Stem Cell Research &Therapy, vol. 3, no. 4, article 35, 2012.
[53] T. E. Foster, B. L. Puskas, B. R. Mandelbaum, M. B. Gerhardt, and S. A. Rodeo, “Platelet-rich plasma: from basic science to clinical applications,” The American Journal of Sports Medicine, vol. 37, no. 11, pp. 2259–2272, 2009.
[54] A. S.Wasterlain, H. J. Braun, A. H. S. Harris, H.-J. Kim, and J. L. Dragoo, “The systemic effects of platelet-rich plasma injection,” The American Journal of Sports Medicine, vol. 41, no. 1, pp. 186– 193, 2013.


Patient Services at ANOVA Institute for Regenerative Medicine

Located in the center of Germany, quick access by car or train from anywhere in Europe

Simple access worldwide, less than 20 minutes from Frankfurt Airport

Individualized therapy with state-of-the-art stem cell products

Individually planned diagnostic work-up which include world-class MRI and CT scans

German high quality standard on safety and quality assurance

Personal service with friendly, dedicated Patient Care Managers

Scientific collaborations with academic institutions to assure you the latest regenerative medical programs